

Patient Consent Management in Long Term Follow Up Trials

Team: Alice Morgensztern, Caroline Liu, Gianfranco Lucchesi, Ian Chiang

....

Al-powered real world data-driven company for health prediction and diagnosis

Manages clinical trials for cancer drugs and regulatory drug prescriptions

\$150 million raised **

The Company

\$1.9 billion valuation

Long-term Follow-up Trials

Understanding the long term effects of a health intervention

- Current TAM: \$36 million (0.12% * of on-going clinical trials)
- Estimated TAM in 2030: \$235 million
- Need for specific * data and consent tracking processes





The Blockchain

Already used in healthcare for patient tokenization. Allows for the creation of a smart contract that can automatically enforce its terms.

- Secured
 - * Decentralized Immutable ** Customizable





The Solution

Four stakeholders:

- Concert Al *
- Patient Third party ✨ * One platform with two interfaces:

Sponsor

- Request access to data.
- Manage patient consent through a smart contract, potentially combining with patient token and NFTs

Business plan

Two possibilities: build in-house or partner.

In both cases, the biggest costs are probably not associated with upfront investment (as it's a common use of the blockchain), but with **integration** into existing solutions and maintenance.